Mometasonfuroat Ratiopharm (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside nasal epithelial cells. The drug‑receptor complex then enters the cell nucleus and alters gene transcription, suppressing the release of inflammatory cytokines, chemokines and adhesion molecules. This reduces swelling, mucus production and immune‑cell infiltration in the nasal mucosa.

The prescribed dose of Mometasonfuroat Ratiopharm is determined by the treating clinician based on the patient’s age, severity of symptoms and response to therapy. The prescriber will provide specific instructions on the number of sprays per nostril and the frequency of administration.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Healthcare professionals generally advise that it should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mometasonfuroat Ratiopharm. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mometasonfuroat Ratiopharm contains mometasone furoate, which is a high‑potency, once‑daily nasal corticosteroid. Compared with lower‑potency options such as fluticasone or budesonide, mometasone often provides comparable symptom control with a similar safety profile, but individual response may vary. Choice of agent depends on physician assessment of efficacy, tolerability and patient preference.

Store the nasal spray at room temperature, below 25 °C, in its original packaging. Protect it from moisture, excessive heat and direct sunlight. Keep the device upright when not in use and ensure the cap is securely closed to maintain sterility and spray performance.

The spray is administered directly into each nostril. The patient should gently blow their nose, tilt the head slightly forward, insert the tip into a nostril, and press the actuator while breathing in gently through the nose. The prescribed number of sprays per nostril is repeated for the other side, following the clinician’s directions.

Serious adverse events, although rare, include adrenal suppression with prolonged high‑dose use, severe or persistent nosebleeds, fungal infection of the nasal passages, perforation of the nasal septum and systemic allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience unusual bleeding, vision changes, severe headache or signs of an allergic reaction.

Individuals with known hypersensitivity to mometasone furoate, any component of the formulation, or other corticosteroids should avoid this product. It is also contraindicated in patients with active untreated fungal, viral or bacterial infections of the nasal mucosa until the infection has been adequately treated.